Schwartz Awarded Top ISOPP Honor
Rowena "Moe Schwartz, PharmD, associate professor of pharmacy practice within the James L. Winkle College of Pharmacy and pharmacist for the University of Cincinnati (UC) Cancer Institutes Phase I Experimental Therapeutics Program, received the Helen McKinnon Award at the 2018 International Society of Oncology Practitioners (ISOPP) Annual General Meeting April 12, 2018.
This award was created to honor Helen McKinnon who was instrumental in the formation of ISOPP and is given to those who promote and enhance oncology pharmacy practice worldwide in order to improve cancer patient care.
Schwartz, who joined the Winkle College of Pharmacy in 2016, teaches oncology pharmacy therapeutics and practice and works with students during their advanced pharmacy practice experiences. Additionally, she works as part of the UC Medical Centers oncology pharmacy team at the UC Health Barrett Cancer Center patient care facility in ambulatory oncology.
"This is a pretty incredible accomplishment. (Dr. Schwartz) is a huge asset to our clinics, says Trisha Wise-Draper, PhD, assistant professor of medicine in the Division of Hematology Oncology and medical director of the UC Cancer Institutes Clinical Trials Office.
Tags
Related Stories
UC experts say proper produce washing is key defense against Cyclospora
July 17, 2026
Hamilton County Public Health reports confirmed cases of cyclosporiasis, as concerns persist. Cyclospora is a parasite that can cause a stomach illness lasting days — sometimes even weeks. University of Cincinnati medical experts say it is usually linked to contaminated water or food, often fresh produce.
UC students organize free health clinic in community
July 15, 2026
The University of Cincinnati student chapter of Remote Area Medical held its annual free health clinic July 11-12 at St. Xavier High School. Medical, dental and vision care was offered to adults and children, with no income requirements or insurance needed.
University of Cincinnati advances FLASH radiation therapy with new clinical trial
July 15, 2026
UC Cancer Center researchers led the FAST-02 trial, showing ultra-high-dose-rate FLASH proton therapy near the heart and lungs safely reduced pain from thoracic bone metastases.